Cargando…
Successfully Navigating Food and Drug Administration Orphan Drug and Rare Pediatric Disease Designations for AAV9-hPCCA Gene Therapy: The National Institutes of Health Platform Vector Gene Therapy Experience
Orphan drug designation (ODD) is an important program intended to facilitate the development of orphan drugs in the United States. An orphan drug benefiting pediatric patients can qualify as a drug for a Rare Pediatric Disease Designation (RPDD) as well. The ODD and RPDD programs provide financial i...
Autores principales: | Lomash, Richa Madan, Shchelochkov, Oleg, Chandler, Randy J., Venditti, Charles P., Pariser, Anne R., Ottinger, Elizabeth A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc., publishers
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10031144/ https://www.ncbi.nlm.nih.gov/pubmed/36694456 http://dx.doi.org/10.1089/hum.2022.232 |
Ejemplares similares
-
The Platform Vector Gene Therapies Project: Increasing the Efficiency of Adeno-Associated Virus Gene Therapy Clinical Trial Startup
por: Brooks, Philip J., et al.
Publicado: (2020) -
Functional Analysis of the PCCA and PCCB Gene Variants Predicted to Affect Splicing
por: Bychkov, Igor, et al.
Publicado: (2021) -
Gene therapy for metabolic diseases
por: Chandler, Randy J., et al.
Publicado: (2016) -
Gene therapy in a murine model of Methylmalonic Acidemia (MMA) using rAAV9 mediated gene delivery
por: Sénac, J S, et al.
Publicado: (2011) -
Case reports: three novel variants in PCCA and PCCB genes in Chinese patients with propionic acidemia
por: Yang, Qi, et al.
Publicado: (2020)